½ÃÀ庸°í¼­
»óǰÄÚµå
1324830

¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¹Ãø(-2030³â) - À¯Çü, ±â¼ú, ¿¬·É´ë, ¼­ºñ½ºº° ±¹°¡ ºÐ¼®

US and Europe Surrogacy Market Forecast to 2030 - Country Analysis by Type, Technology, Age Group, and Service Order

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 156 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå±Ô¸ð´Â 2022³â 61¾ï 1,372¸¸ ´Þ·¯¿¡¼­ 2030³â 252¾ï 8,402¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 19.4%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÒÀÓ È¯ÀÚÀÇ Áõ°¡¿Í ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¹Ì±¹°ú À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´ë¸®¸ðÀÇ »ó¾÷È­´Â ÇâÈÄ ¸î ³â µ¿¾È ¹Ì±¹°ú À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ë¸®¸ð Ãâ»êÀº ¿©¼ºÀÌ ´Ù¸¥ °³ÀÎÀ̳ª ºÎºÎ¸¦ ´ë½ÅÇÏ¿© ÀӽŰú Ãâ»êÀ» ÇÏ´Â °ÍÀ¸·Î, ÀϹÝÀûÀ¸·Î ÀǵµµÈ ºÎ¸ð¶ó°í ÇÕ´Ï´Ù. ºÎºÎ°¡ ½º½º·Î ÀÓ½ÅÀ» ¿øÇÏÁö ¾Ê´Â °æ¿ì, ÀÓ½ÅÀÌ ¹°¸®ÀûÀ¸·Î ºÒ°¡´ÉÇÑ °æ¿ì, ÀÓ½ÅÀÇ À§ÇèÀÌ »ê¸ð¿¡°Ô À§ÇèÇÑ °æ¿ì, µ¶½Å ³²¼ºÀ̳ª ³²¼º ºÎºÎ°¡ ¾ÆÀ̸¦ °®±â¸¦ ¿øÇÒ ¶§ »ç¶÷µéÀº ´ë¸®¸ð¸¦ ã´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù.

ºÒÀÓÄ¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀ强Àå¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù.

À¯Àü, ¸é¿ª¼º ºÒÀÓ, ¼ºº´(STI), ³­°ü Æó¼â, Àڱà ±ÙÁ¾ µîÀº ºÒÀÓÀ» À¯¹ßÇÏ´Â ¿äÀÎ Áß ÀϺÎÀ̸ç, CDC°¡ ¹ßÇ¥ ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 8 ½Ö Áß 1 ½ÖÀÌ Àӽſ¡ ¾î·Á¿òÀ» °Þ°í ÀÖÀ¸¸ç, Áï ±âÈ¥ ¿©¼ºÀÇ 12 % ÀÌ»óÀÌ ÀÓ½ÅÀ» ´Þ¼ºÇϱâ À§ÇØ ÇÕº´Áõ¿¡ Á÷¸é ÇØ ÀÖ´Ù°íÇÕ´Ï´Ù. 2023³â Medical Lifesciences Àú³Î¿¡ ¹ßÇ¥µÈ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¿µ±¹¿¡¼­´Â 7½Ö Áß 1½ÖÀÇ ºÎºÎ°¡ ÀÌ ¹®Á¦¸¦ °Þ°í ÀÖÀ¸¸ç, ÃÑ 350¸¸ ¸íÀÌ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ´ë¸®¸ð¸¦ Æ÷ÇÔÇØ ºÒÀÓÀ» ±Øº¹ÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ ¼±ÅÃÁö°¡ ÀÖ´Ù´Â »ç½ÇÀ» ¾Æ´Â »ç¶÷µéÀÌ ´Ã¾î³ª¸é¼­ ´ë¸®¸ð ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿©·¯ ¹Î°£ ¹× °ø°ø ´Üü´Â ü¿Ü¼öÁ¤(IVF), Àڱà ³» Àΰø¼öÁ¤(IUI) µîÀÇ ¹æ¹ýÀ» È«º¸ÇÏ´Â ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÅëÇØ ºÒÀÓ°ú ±× Ä¡·á¿¡ ´ëÇÑ ÀνÄÀ» È®»ê½Ã۰í ÀÖ½À´Ï´Ù. ¹Ì±¹ Fertility´Â ¸Å³â 4¿ù ¸¶Áö¸· ÁÖ¿¡ ¿­¸®´Â National Infertility Awareness Week(NIAW)¿¡ ºÒÀÓÀ¸·Î °í¹ÎÇÏ´Â »ç¶÷µé¿¡°Ô Âü¿©¸¦ µ¶·ÁÇϰí ÀÖ½À´Ï´Ù. IVF Florida, Reproductive Science Centre of the San Francisco Bay Area(RSC), Shady Grove Fertility(SGF)¿¡¼­´Â ÀÇ»çµéÀÌ ÁÖÃÖÇÏ´Â Çà»ç¸¦ °³ÃÖÇϰí ȯÀÚµéÀ» À§ÇÑ ±³À° ÀڷḦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, À¯·´¿¡¼­´Â ¸Å³â 11¿ù¿¡ À¯·´ ºÒÀÓ ÁÖ°£À» °³ÃÖÇÏ¿© ºÒÀÓ¿¡ ´ëÇÑ ÀνÄÀ» Á¦°íÇϰí ÀÖ½À´Ï´Ù. ÀÌó·³ ºÒÀÓ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀåÀÌ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

³ôÀº ºñ¿ëÀÌ ¹Ì±¹°ú À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

¸¹Àº °³Àΰú ºÎºÎ°¡ ÀÇ·áºñ°¡ »ó´ëÀûÀ¸·Î Àú·ÅÇÑ ±¹°¡¿¡¼­ ±¹Á¦ ´ë¸®¸ð¸¦ ¼±ÅÃÇÕ´Ï´Ù. Àεµ, ¿ìÅ©¶óÀ̳ª, µ¿³²¾Æ½Ã¾Æ ±¹°¡ µîÀº Àú·ÅÇÑ ´ë¸®¸ð¸¦ ã´Â »ç¶÷µé¿¡°Ô ÀαâÀÖ´Â ±¹°¡ÀÔ´Ï´Ù. ÀÌµé ±¹°¡´Â ÀÇ·áºñ°¡ Àú·ÅÇϰí, ¹ýÀû ¿ä°ÇÀÌ ¾ö°ÝÇÏÁö ¾ÊÀ¸¸ç, ´ë¸®¸ð¿¡ ´ëÇÑ º¸¼ö°¡ ³·±â ¶§¹®¿¡ Àüü ÁöÃâÀ» ÁÙÀÏ ¼ö ÀÖ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÇ·á°ü±¤ ÄÁ¼³ÆÃ ȸ»çÀÎ IVF Conception¿¡ µû¸£¸é ÀεµÀÇ ´ë¸®¸ð ºñ¿ëÀº 12-15¸¸ Àεµ ·çÇÇ(15,000-21,000´Þ·¯)·Î ¹Ì±¹À̳ª µ¿À¯·´ ±¹°¡µé¿¡ ºñÇØ »ó´çÈ÷ Àú·ÅÇÕ´Ï´Ù. ¹Ý¸é ¹Ì±¹°ú ¿ìÅ©¶óÀ̳ª µî µ¿À¯·´ ±¹°¡ÀÇ ´ë¸®¸ð ºñ¿ëÀº °¢°¢ 95,000-150,000´Þ·¯, 45,000-55,000´Þ·¯ÀÔ´Ï´Ù.

¶ÇÇÑ, ´ë¸®¸ð Ãâ»ê ÀýÂ÷¿¡´Â ¸¹Àº ºñ¿ëÀÌ ¼Ò¿äµË´Ï´Ù. ´ë¸®¸ð¸¦ ¿øÇÏ´Â ºÎ¸ð´Â ¸ðµç ¹ýÀû Ãø¸éÀÌ ÀûÀýÇÏ°Ô Ã³¸®µÉ ¼ö ÀÖµµ·Ï ´ë¸®¸ð¹ý Àü¹®°¡¿Í »ó´ãÇØ¾ß ÇÕ´Ï´Ù. ¿©±â¿¡´Â °è¾à¼­ ÀÛ¼º ¹× °ËÅä, ÇÊ¿äÇÑ Çã°¡ ¹× ¼­·ù Ãëµæ, ´ë¸®¸ð¸¦ µÑ·¯½Ñ º¹ÀâÇÑ ¹ýÀû »óȲ ÆÄ¾Ç µîÀÌ Æ÷ÇԵ˴ϴÙ. ±× ¿ÜÀÇ ºÎ´ëºñ¿ëÀ¸·Î´Â ´ë¸®ºÎ¸ðÀÇ ¿©Çà °æºñ, ¼÷¹Ú Áغñ, º¸Çè °¡ÀÔ, ¿©Çà Áß ¹ß»ýÇÒ ¼ö ÀÖ´Â Ãß°¡Àû µ¹¹ß »óȲ µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºñ¿ëÀº °³º°ÀûÀÎ »óȲ°ú °è¾àÀÇ ±¸Ã¼ÀûÀÎ ¿ä±¸ »çÇ׿¡ µû¶ó ´Þ¶óÁú ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ³ôÀº ´ë¸®¸ð ºñ¿ëÀº ÀϺΠ¿¹ºñ ºÎ¸ð¿¡°Ô À庮ÀÌ µÇ¾î Àüü ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÃÖ±Ù ¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡¼­ ÀÌ·ïÁø ¸î °¡Áö °³¹ß »ç·Ê¸¦ »ìÆìº¸¸é ´ÙÀ½°ú °°½À´Ï´Ù:

2023³â 3¿ù, ¹Ì±¹ Fertility´Â Ovation Fertility¿Í Á¦ÈÞÇÏ¿© ü¿Ü¼öÁ¤ ¼­ºñ½º °­±¹À» °Ç¼³ÇÏ°í ºÒÀÓ Ä¡·á ¼­ºñ½º Á¢±Ù¼ºÀ» ³ôÀÏ °ÍÀÔ´Ï´Ù. ¾ç»ç´Â ÃÖÁ¾ °è¾àÀ» ü°áÇÏ°í ¿¬¹æ ±ÔÁ¦ ´ç±¹ÀÇ Æò°¡ ÀýÂ÷¸¦ ¿Ï·áÇÏ¿© ¹Ì±¹À» ¼±µµÇÏ´Â ºÒÀÓ Ä¡·á Ç÷§ÆûÀÌ Åº»ýÇß½À´Ï´Ù.

2023³â 5¿ù, ·±´ø ¿©¼º Ŭ¸®´ÐÀº ÄÝü½ºÅÍ¿¡ »õ·Î¿î ºÒÀÓ Å¬¸®´ÐÀ» °³¼³Çß½À´Ï´Ù. À̸¦ ÅëÇØ ȸ»ç´Â ¿¡¼½½º Ä«¿îƼ¿Í ÁÖº¯ Áö¿ªÀ» ÅëÇØ ¼¼°èÀû ¼öÁØÀÇ ºÒÀÓ Ä¡·á¸¦ ÀÚ¶û½º·´°Ô È®ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡ ´ëÇÑ ÀλçÀÌÆ®

¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀåÀº À¯Çüº°·Î ÀüÅëÀû ´ë¸®¸ð¿Í ÀӽŠ´ë¸®¸ð·Î ±¸ºÐµÇ¸ç, 2022³â ¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡¼­ ÀӽŠ´ë¸®¸ð°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå- ±â¼úÀû ÀλçÀÌÆ®

¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀåÀº ±â¼ú¿¡ µû¶ó Àڱà ³» Àΰø¼öÁ¤°ú ü¿Ü¼öÁ¤À¸·Î ±¸ºÐµÇ¸ç, 2022³â ¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡¼­ ü¿Ü¼öÁ¤ ºÐ¾ß°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀåÀÇ ¿¬·É´ëº° ÀλçÀÌÆ®

¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀåÀº ¿¬·É´ëº°·Î 35¼¼ ÀÌÇÏ, 35-37¼¼, 38-39¼¼, 40-42¼¼, 43-44¼¼, 44¼¼ ÀÌ»óÀ¸·Î ±¸ºÐµÇ¸ç, 2022³â¿¡´Â 35¼¼ ÀÌÇϰ¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼­ºñ½º ÁÖ¹® ¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀåÀ» ±â¹ÝÀ¸·Î ÇÑ ÀλçÀÌÆ®

¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀåÀº ¼­ºñ½º ÁÖ¹®¿¡ µû¶ó º´¿ø, ºÒÀÓ Å¬¸®´Ð, ±âŸ·Î ±¸ºÐµÇ¸ç, ºÒÀÓ Å¬¸®´ÐÀÌ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO), ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC), ¹Ì±¹ ºÒÀÓ ¼­ºñ½º(American Fertility Services) µîÀº ¹Ì±¹ ¹× À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡ ´ëÇÑ º¸°í¼­¸¦ ÀÛ¼ºÇÒ ¶§ Âü°íÇÑ ÁÖ¿ä 1Â÷ ¹× 2Â÷ Á¤º¸ Áß ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå - ¿äÁ¡

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå - ½ÃÀå »óȲ

  • °³¿ä
  • PEST ºÐ¼®
    • ¹Ì±¹ - PEST ºÐ¼®
    • À¯·´ - PEST ºÐ¼®

Á¦5Àå ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ºÒÀÓ È¯ÀÚ¼ö Áõ°¡
    • ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä È®»ê
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ºÒÀÓ Ä¡·á¿¡ °É¸®´Â ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • »ý½Ä ±â¼úÀÇ ±â¼úÀû Áøº¸
  • ÇâÈÄ µ¿Çâ
    • ´ë¸®¸ð Ãâ»ê »ó¾÷È­
  • ¿µÇ⠺м®

Á¦6Àå ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå ºÐ¼®

  • ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå ¸ÅÃâ°ú ¿¹Ãø ºÐ¼®
  • ºñ¿ë ºÐ¼®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
    • ¹Ì±¹
    • ÀÌÅ»¸®¾Æ
    • ¿µ±¹
    • µ§¸¶Å©
    • ³×´ú¶õµå
    • ¾ÆÀÏ·£µå

Á¦7Àå ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå ºÐ¼® - À¯Çüº°

  • ÀÓ½ÅÁß ´ë¸®¸ð Ãâ»ê
  • ÀüÅëÀû ´ë¸®¸ð Ãâ»ê

Á¦8Àå ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå ºÐ¼® - ±â¼úº°

  • Àڱó» Àΰø¼öÁ¤(IUI)
  • ü¿Ü¼öÁ¤(IVF)

Á¦9Àå ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå ºÐ¼® - ¿¬·ÉÃþº°

  • 35¼¼ ÀÌÇÏ
  • 37¼¼ ÀÌÇÏ
  • 39¼¼ ÀÌÇÏ
  • 42¼¼ ÀÌÇÏ
  • 44¼¼ ÀÌÇÏ
  • 44¼¼ ÀÌ»ó

Á¦10Àå ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå ºÐ¼® - ¼­ºñ½º ¿À´õº°

  • º´¿ø
  • ºÒÀÓ Ä¡·á Ŭ¸®´Ð
  • ±âŸ

Á¦11Àå ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå - Áö¿ª ºÐ¼®

  • À¯·´
    • À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå : À¯Çüº°, 2020-2030³â
    • À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ±â¼úº°, 2020-2030³â
      • À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ü¿Ü¼öÁ¤(±â¼úº°), 2020-2030³â
    • À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ¿¬·ÉÃþº°, 2020-2030³â
    • À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ¼­ºñ½º ¿À´õº°, 2020-2030³â
    • À¯·´ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ±¹°¡º°
      • ÀÌÅ»¸®¾Æ
      • ¿µ±¹
      • µ§¸¶Å©
      • ³×´ú¶õµå
      • ¾ÆÀÏ·£µå
      • ±âŸ À¯·´
  • ¹Ì±¹
    • ¹Ì±¹ ´ë¸®¸ð Ãâ»ê ½ÃÀå : À¯Çüº°, 2020-2030³â
    • ¹Ì±¹ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ±â¼úº°, 2020-2030³â
      • ¹Ì±¹ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ü¿Ü¼öÁ¤(±â¼úº°), 2020-2030³â
    • ¹Ì±¹ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ¿¬·ÉÃþº°, 2020-2030³â
    • ¹Ì±¹ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ¼­ºñ½º ¿À´õº°, 2020-2030³â

Á¦12Àå COVID-19 ÆÒµ¥¹ÍÀÌ ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ

  • ¹Ì±¹
  • À¯·´

Á¦13Àå ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå - ¾÷°è »óȲ

  • ¹Ì±¹ ¹× À¯·´ÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå ¼ºÀå Àü·«(%)
  • À¯±âÀû Àü°³
  • ¹«±âÀû Àü°³

Á¦14Àå ±â¾÷ °³¿ä

  • London Women's Clinic Ltd
  • The Centre for Reproductive and Genetic Health Ltd
  • Miracle Baby Surrogacy
  • Lotus Surrogacy
  • VittoriaVita LLC
  • Sensible Surrogacy
  • New Life Ukraine
  • Redia Ltd
  • Circle Surrogacy LLC
  • Ovation Fertility

Á¦15Àå ºÎ·Ï

ksm 23.10.23

The US and Europe surrogacy market size is expected to grow from US$ 6,113.72 million in 2022 to US$ 25,284.02 million by 2030; it is estimated to register a CAGR of 19.4% from 2022 to 2030.

The increase in infertility cases and growing awareness of the treatment of fertility drive the US and Europe surrogacy market growth. Also, commercialization of surrogacy is expected to fuel the US and Europe surrogacy market growth in the coming years.

Surrogacy is a practice where a woman carries a pregnancy and gives birth to a child on behalf of another individual or couple, commonly referred to as intended parents. When a couple doesn't want to bear the pregnancy themselves, when pregnancy is physically impossible, when pregnancy risks are risky for the intended mother, or when a single man or a male couple wants to have a kid, people may investigate surrogacy arrangements.

Growing Awareness of Treatment of Infertility is fueling the growth of the US and Europe Surrogacy Market

Genetics, immune infertility, sexually transmitted infections (STIs), tubal blockage, and uterine fibroids are a few of the factors causing infertility. As per data published by CDC, every 1 in 8 couples in the US faces difficulty conceiving, i.e., over 12% of married women face complications in attaining pregnancy. According to data published in Medical Lifesciences in 2023, the problem affects ~1 in 7 couples in the UK, totaling ~3.5 million affected individuals. As more people become aware of the various options available to overcome infertility, including surrogacy, the demand for surrogacy services is increasing. Several private and public organizations are spreading awareness of infertility and its treatment through initiatives promoting procedures such as in vitro fertilization (IVF) and intrauterine insemination (IUI). US Fertility urges those struggling with infertility to participate in National Infertility Awareness Week (NIAW) that is observed throughout the last week of April every year. During the NIAW, the Fertility Centres of Illinois (FCI), IVF Florida, Reproductive Science Centre of the San Francisco Bay Area (RSC), and Shady Grove Fertility (SGF) organize physician-hosted events and arrange educational materials to enlighten patients. Further, Europe observes a European Fertility Week every year in November to raise awareness about infertility. Thus, the increasing number of awareness programs related to infertility treatments boosts the surrogacy market in the US and Europe.

High Cost Involved in Procedure is hampering the US and Europe Surrogacy Market Growth

Many individuals and couples opt for international surrogacy arrangements in countries with comparatively lower healthcare costs. Destinations such as India, Ukraine, or certain Southeast Asian countries have emerged as popular choices for individuals seeking more affordable surrogacy options. These countries often offer lower medical costs, less stringent legal requirements, and lower compensation for surrogate mothers, resulting in reduced overall expenses. According to IVF Conception, a medical tourism consultancy, the cost of a surrogacy procedure in India ranges from 12 to 15 lakh INR (US$ 15,000-21,000), which is substantially low compared to the US and East European countries. On the other hand, the typical cost of surrogacy procedures in the US and eastern European countries, such as Ukraine, ranges from US$ 95,000 to 150,000 and from US$ 45,000 to 55,000, respectively.

Legal fees also lead to significant expenses in the surrogacy process. Intended parents need to approach professionals specializing in surrogacy laws to ensure that all legal aspects are properly handled. This includes drafting and reviewing contracts, obtaining necessary permissions and documentation, and navigating a complex legal landscape surrounding surrogacy. In addition, other miscellaneous expenses include travel costs for intended parents, accommodation arrangements, insurance coverage, and additional contingencies arising throughout the journey. These costs can vary depending on individual circumstances and the specific requirements of the arrangement. Thus, the high cost involved in surrogacy can be a barrier for some intended parents, thereby limiting the overall market growth.

A few of the recent developments in the US and Europe surrogacy market are mentioned below:

In March 2023, US Fertility has joined forces with Ovation Fertility to create IVF services powerhouse and increase the access to fertility services. The two companies signed a definitive agreement and have completed a successful federal regulatory evaluation process, creating the leading fertility platform in the U.S. Together, US Fertility and Ovation provide advanced fertility care through 90+ locations and 28 laboratories.

In May 2023, London Women's Clinic opened their new fertility clinic in Colchester. This will allow the company to proudly expand the world-class fertility care through the county of Essex and its surrounding areas.

Type US and Europe Surrogacy Market-Based Insights

The US and Europe surrogacy market, based on type, is segmented into traditional surrogacy and gestational surrogacy. In 2022, the gestational surrogacy segment held the largest market share in US and Europe surrogacy market. The market for the same segment is expected to grow at the fastest rate in the coming years.

Technology US and Europe Surrogacy Market-Based Insights

The US and Europe surrogacy market, based on technology, is segmented into intrauterine insemination and in-vitro fertilization. In 2022, the in-vitro fertilization segment held the largest market share in US and Europe surrogacy market. The market for the same segment is expected to grow at the fastest rate in the coming years.

Age Group US and Europe Surrogacy Market-Based Insights

The US and Europe surrogacy market, based on age group, is segmented into below 35 years, 35-37 years, 38-39 years, 40-42 years, 43-44 years, and over 44 years. In 2022, the below 35 years segment held the largest market share, and the same segment is expected to grow at the fastest rate during the forecast period.

Service Order US and Europe Surrogacy Market-Based Insights

The US and Europe surrogacy market, based on service order, is segmented into hospitals, fertility clinics, and others. In 2022, the fertility clinics segment held the largest market share, and the same segment is expected to grow at the fastest rate during the forecast period.

The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and to American Fertility Services are a few of the major primary and secondary sources referred to while preparing the report on the US and Europe surrogacy market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the US and Europe surrogacy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the US and Europe surrogacy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the US and Europe surrogacy market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 US and Europe Surrogacy market - by Type
    • 1.3.2 US and Europe Surrogacy market - by Technology
    • 1.3.3 US and Europe Surrogacy market - by Age Group
    • 1.3.4 US and Europe Surrogacy market - by Service Provider
    • 1.3.5 US and Europe Surrogacy market - by Country

2. US and Europe Surrogacy market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. US and Europe Surrogacy market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 US - PEST Analysis
    • 4.2.2 Europe - PEST Analysis

5. US and Europe Surrogacy Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increasing Number of Infertility Cases
    • 5.1.2 Growing Awareness of Treatment of Infertility
  • 5.2 Market Restraints
    • 5.2.1 High Cost Involved in Procedure
  • 5.3 Market Opportunities
    • 5.3.1 Technological Advancements in Reproductive Technologies
  • 5.4 Future Trends
    • 5.4.1 Commercialization of Surrogacy
  • 5.5 Impact Analysis

6. US and Europe Surrogacy market Analysis

  • 6.1 US and Europe Surrogacy market Revenue Forecast and Analysis
  • 6.2 Cost Analysis
  • 6.3 Regulatory Scenario
    • 6.3.1 United States
    • 6.3.2 Italy
    • 6.3.3 UK
    • 6.3.4 Denmark
    • 6.3.5 The Netherlands
    • 6.3.6 Ireland

7. US and Europe Surrogacy Market Analysis - by Type

  • 7.1 Overview
  • 7.2 Gestational Surrogacy
    • 7.2.1 Overview
    • 7.2.2 Gestational Surrogacy: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Traditional Surrogacy
    • 7.3.1 Overview
    • 7.3.2 Traditional Surrogacy: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)

8. US and Europe Surrogacy Market Analysis - by Technology

  • 8.1 Overview
  • 8.2 Intrauterine Insemination (IUI)
    • 8.2.1 Overview
    • 8.2.2 Intrauterine Insemination (IUI): US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 In-Vitro Fertilization (IVF)
    • 8.3.1 Overview
    • 8.3.2 In-Vitro Fertilization (IVF): US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.3.3 Classical/Standard IVF
      • 8.3.3.1 Overview
      • 8.3.3.2 Classical/Standard IVF: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.3.4 Intracytoplasmic Sperm Injection (ICSI)
      • 8.3.4.1 Overview
      • 8.3.4.2 Intracytoplasmic Sperm Injection (ICSI): US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)

9. US and Europe Surrogacy Market Analysis - by Age Group

  • 9.1 Overview
  • 9.2 Below 35 Years
    • 9.2.1 Below 35 Years: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3-37 Years
    • 9.3.1-37 Years: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4-39 Years
    • 9.4.1-39 Years: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5-42 Years
    • 9.5.1-42 Years: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6-44 Years
    • 9.6.1-44 Years: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.7 Over 44 Years
    • 9.7.1 Over 44 Years: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)

10. US and Europe Surrogacy Market Analysis - by Service Order

  • 10.1 Overview
  • 10.2 Hospitals
    • 10.2.1 Overview
    • 10.2.2 Hospitals: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Fertility Clinics
    • 10.3.1 Overview
    • 10.3.2 Fertility Clinics: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.4 Others
    • 10.4.1 Overview
    • 10.4.2 Others: US and Europe Surrogacy Market - Revenue and Forecast to 2030 (US$ Million)

11. US and Europe Surrogacy Market - Regional Analysis

  • 11.1 Europe
    • 11.1.1 Overview
    • 11.1.2 Europe Surrogacy Market Revenue and Forecasts to 2030 (US$ Mn)
    • 11.1.3 Europe Surrogacy Market, by Type, 2020-2030 (US$ Million)
    • 11.1.4 Europe Surrogacy Market, by Technology, 2020-2030 (US$ Million)
      • 11.1.4.1 Europe Surrogacy Market, for IVF by Technology, 2020-2030 (US$ Million)
    • 11.1.5 Europe Surrogacy Market, by Age Group, 2020-2030 (US$ Million)
    • 11.1.6 Europe Surrogacy Market, by Service Order, 2020-2030 (US$ Million)
    • 11.1.7 Europe Surrogacy Market, by Country
      • 11.1.7.1 Italy
        • 11.1.7.1.1 Overview
        • 11.1.7.1.2 Italy Surrogacy Market Revenue and Forecasts to 2030 (US$ Mn)
        • 11.1.7.1.3 Italy Surrogacy Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.1.4 Italy Surrogacy Market, by Technology, 2020-2030 (US$ Million)
        • 11.1.7.1.4.1 Italy Surrogacy Market, for IVF by Technology, 2020-2030 (US$ Million)
        • 11.1.7.1.5 Italy Surrogacy Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.7.1.6 Italy Surrogacy Market, by Service Order, 2020-2030 (US$ Million)
      • 11.1.7.2 UK
        • 11.1.7.2.1 Overview
        • 11.1.7.2.2 UK Surrogacy Market Revenue and Forecasts to 2030 (US$ Mn)
        • 11.1.7.2.3 UK Surrogacy Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.2.4 UK Surrogacy Market, by Technology, 2020-2030 (US$ Million)
        • 11.1.7.2.4.1 UK Surrogacy Market, for IVF by Technology, 2020-2030 (US$ Million)
        • 11.1.7.2.5 UK Surrogacy Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.7.2.6 UK Surrogacy Market, by Service Order, 2020-2030 (US$ Million)
      • 11.1.7.3 Denmark
        • 11.1.7.3.1 Overview
        • 11.1.7.3.2 Denmark Surrogacy Market Revenue and Forecasts to 2030 (US$ Mn)
        • 11.1.7.3.3 Denmark Surrogacy Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.3.4 Denmark Surrogacy Market, by Technology, 2020-2030 (US$ Million)
        • 11.1.7.3.4.1 Denmark Surrogacy Market, for IVF by Technology, 2020-2030 (US$ Million)
        • 11.1.7.3.5 Denmark Surrogacy Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.7.3.6 Denmark Surrogacy Market, by Service Order, 2020-2030 (US$ Million)
      • 11.1.7.4 The Netherlands
        • 11.1.7.4.1 Overview
        • 11.1.7.4.2 The Netherlands Surrogacy Market Revenue and Forecasts to 2030 (US$ Mn)
        • 11.1.7.4.3 The Netherlands Surrogacy Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.4.4 The Netherlands Surrogacy Market, by Technology, 2020-2030 (US$ Million)
        • 11.1.7.4.4.1 The Netherlands Surrogacy Market, for IVF by Technology, 2020-2030 (US$ Million)
        • 11.1.7.4.5 The Netherlands Surrogacy Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.7.4.6 The Netherlands Surrogacy Market, by Service Order, 2020-2030 (US$ Million)
      • 11.1.7.5 Ireland
        • 11.1.7.5.1 Overview
        • 11.1.7.5.2 Ireland Surrogacy Market Revenue and Forecasts to 2030 (US$ Mn)
        • 11.1.7.5.3 Ireland Surrogacy Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.5.4 Ireland Surrogacy Market, by Technology, 2020-2030 (US$ Million)
        • 11.1.7.5.4.1 Ireland Surrogacy Market, for IVF by Technology, 2020-2030 (US$ Million)
        • 11.1.7.5.5 Ireland Surrogacy Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.7.5.6 Ireland Surrogacy Market, by Service Order, 2020-2030 (US$ Million)
      • 11.1.7.6 Rest of Europe
        • 11.1.7.6.1 Overview
        • 11.1.7.6.2 Rest of Europe Surrogacy Market Revenue and Forecasts to 2030 (US$ Mn)
        • 11.1.7.6.3 Rest of Europe Surrogacy Market, by Type, 2020-2030 (US$ Million)
        • 11.1.7.6.4 Rest of Europe Surrogacy Market, by Technology, 2020-2030 (US$ Million)
        • 11.1.7.6.4.1 Rest of Europe Surrogacy Market, for IVF by Technology, 2020-2030 (US$ Million)
        • 11.1.7.6.5 Rest of Europe Surrogacy Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.7.6.6 Rest of Europe Surrogacy Market, by Service Order, 2020-2030 (US$ Million)
  • 11.2 United States
    • 11.2.1 Overview
    • 11.2.2 US Surrogacy Market Revenue and Forecasts to 2030 (US$ Mn)
    • 11.2.3 US Surrogacy Market, by Type, 2020-2030 (US$ Million)
    • 11.2.4 US Surrogacy Market, by Technology, 2020-2030 (US$ Million)
      • 11.2.4.1 US Surrogacy Market, for IVF by Technology, 2020-2030 (US$ Million)
    • 11.2.5 US Surrogacy Market, by Age Group, 2020-2030 (US$ Million)
    • 11.2.6 US Surrogacy Market, by Service Order, 2020-2030 (US$ Million)

12. Impact Of COVID-19 Pandemic on U.S. and Europe Surrogacy Market

  • 12.1 U.S.: Impact Assessment of COVID-19 Pandemic
  • 12.2 Europe: Impact Assessment of COVID-19 Pandemic

13. USA & Europe Surrogacy Market - Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in USA & Europe Surrogacy Market (%)
  • 13.3 Organic Developments
    • 13.3.1 Overview
  • 13.4 Inorganic Developments
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 London Women's Clinic Ltd
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 The Centre for Reproductive and Genetic Health Ltd
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Miracle Baby Surrogacy
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Lotus Surrogacy
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 VittoriaVita LLC
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Sensible Surrogacy
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 New Life Ukraine
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Redia Ltd
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 Circle Surrogacy LLC
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 Ovation Fertility
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦